×

Us­ing the es­ke­t­a­mine list price of $295 per 28 mg in­tranasal de­vice, the treat­ment’s use re­sults in an in­cre­men­tal cost-​effectiveness ra­tio of ap­prox­i­mately $198,000 per QALY com­pared to no ad­di­tional treat­ment, ex­ceed­ing the com­monly cited cost-​effectiveness thresh­olds of be­tween $50,000-​$150,000 per QALY. Mean­while, es­ke­t­a­mine is es­ti­mated to cost ap­prox­i­mately $2.6 mil­lion per life year gained, ICER found. Es­ke­t­a­mine’s ap­proval was also meant to en­hance ac­cess to treat­ment — since ke­t­a­mine is not cov­ered by health in­sur­ers — al­though there is a con­cern that there may still be high out-​of-pocket ex­penses through de­ductibles or non-​coverage poli­cies. In­deed, “the place for es­ke­t­a­mine may de­pend on the com­par­a­tive ben­e­fits be­tween es­ke­t­a­mine and other avail­able treat­ments, such as ke­t­a­mine. Un­for­tu­nately, such in­for­ma­tion is not avail­able at this time,” ICER said. - https://endpts.com/icer-chastises-jj-for-overpricing-depression-drug-esketamine-where-there-is-such-need-for-treatment/?utm_medium=email&utm_campaign=Friday%20May%2010%202019&utm_content=Friday%20May%2010%202019+CID_6f8e1cfb3964e6c54c6241b5a8f0293f&utm_source=ENDPOINTS%20emails&utm_term=ICER%20chastises%20JJ%20for%20overpricing%20depression%20drug%20esketamine%20where%20there%20is%20such%20need%20for%20treatment

Tags: medicalindustrialcomplex antidepressants

Learn More

Learn More

Learn More
0
0
Powered by Pullquote.com